The ultra-short-acting opioid remifentanil is often used as a sole agent for brief and painful procedures associated with little postoperative pain such as extracorporeal shock wave lithotripsy (ESWL). 1 2 It is also used as a supplemental drug during the performance of eye or peripheral nerve blocks.
3±6
Remifentanil is bene®cial in these settings because of its minimal postanaesthetic sedation effects. However, several studies have shown that remifentanil anaesthesia can be associated with postoperative nausea and vomiting (PONV) which prolongs postanaesthetic recovery in a high number (15±50%) of patients. 1 2 7 8 In addition, patients' satisfaction with the anaesthetic technique will be reduced when PONV occurs.
Midazolam and propofol have shown to reduce these symptoms when infused in combination with remifentanil. 2 9 Because the emetic effect of remifentanil seems to be dose-dependent, 5 part of the antiemetic effect of these agents could be explained by the remifentanil dose sparing effect. Also, propofol itself may have antiemetic effects. However, the combination of these drugs with remifentanil increases the rate and severity of respiratory depression. An alternative is the prophylactic use of an antiemetic such as the 5-HT3 antagonist dolasetron, which has good antiemetic ef®cacy without sedative side-effects. 10±13 Therefore, in a prospective, randomized and double-blind trial we tested the hypothesis that dolasetron 12.5 mg before remifentanil infusion may reduce the frequency and intensity of nausea and time to`home readyness' after ambulatory ESWL.
Methods
After approval of the local ethics committee and written informed consent were obtained, 40 patients (ASA class I±II, aged 20±77 yr) undergoing elective ESWL were included the study. Exclusion criteria were ASA class bIII and obstructive pulmonary disease. All patients were asked for risk factors for PONV (Table 1) . After arriving in the anaesthetic room and insertion of an i.v. cannula, baseline assessments of ventilatory frequency, heart rate (ECG), noninvasive arterial pressure, pulse oximetry (Sa O 2 ), main¯ow end-tidal carbon dioxide partial pressure (E¢ CO 2 ) via oxygen face mask were performed using a multifunctional monitor system (Eagle, 3000Ô Marquette Hellige, Germany). According to randomization, patients in Group A rescue dose of droperidol 1.25 mg i.v. was given in case of persistent symptoms (nausea VAS >10 mm for 10 min) in the postanaesthesia care unit (PACU). After completion of the procedure, patients were transferred to the PACU, where they stayed for 60 min. Discharge criteria were assessed every 10 min. Discharge ability was assessed with a postanaesthesia discharge score b9.
14 On the basis of retrospective data from our institution and the literature in the same patient population, a power analysis was performed by using the proportion of complete responders following the procedure as the primary outcome variable. Complete responders were de®ned as patients with no emetic episodes, no rescue medication and a maximum VAS of`5 mm (VAS ranging from 0 to 100 mm) within 24 h according to the published data of other study groups. 10 15 We set 50% as the predicted value for the placebo group. We de®ned the smallest difference to be clinically signi®cant as 25% (a=0.05, b=0.20). This analysis indicated that a sample size of at least 56 patients per group was necessary. An interim analysis was performed 
Results
Groups did not differ with respect to patient characteristics, risk factors for PONV and duration or doses of intraoperative remifentanil infusion ( Table 1 ). The intraoperative frequency of respiratory side-effects did not differ between groups. During the ®rst 60 min after the end of the procedure, the frequency of nausea (>5 mm VAS) and retching was less in patients after dolasetron prophylaxis when compared (Fig. 1) . The mean maximum intensity of nausea was also reduced in the dolasetron group (Fig. 2) . 
Discussion
The present study demonstrates that dolasetron prophylaxis before single use of remifentanil for ESWL can reduce discharge times and the frequency and intensity of PONV. Studies have demonstrated that the single use of remifentanil is associated with an increased rate of PONV when compared with other anaesthetic regimens. 2 7 Although remifentanil was ef®cacious intraperatively, PONV decreased patients' satisfaction. Also, postanaesthesia recovery time was prolonged. Several studies have demonstrated that dolasetron is an effective and well-tolerated preventive treatment for PONV.
16±19
Studies have 13 20 found that i.v. dolasetron 12.5 mg was the maximally effective dose for preventing PONV so we chose this dose for our present study. In addition this regimen was found to be as effective as i.v. dolasetron 25 mg, i.v. ondansetron 4 mg, or i.v. ondansetron 8 mg in preventing emetic symptoms after otolaryngologic surgery. 21 In common with others, 13 15 we chose the proportion of complete responders [no emetic episodes in 24 h (`5 mm VAS)] and the maximum nausea (VAS), following the procedure as the primary outcome variable. As expected, antiemetic prophylaxis with dolasetron 12.5 mg did not completely prevent PONV after remifentanil infusion for ESWL in our study, but was able to reduce the incidence and intensity of postoperative nausea and retching signi®-cantly with an increased total response in comparison with placebo during the ®rst 24 h. As with other studies of remifentanil for monitored anaesthesia care in patients undergoing ESWL, the frequency of persisting nausea and vomiting was low. Joo and collegues 2 described 27% of patients with nausea but only 3% of them vomited during postoperative period. Nausea and vomiting do not usually occur during remifentanil infusion. Therefore, remifentanil infusion is still a suitable technique. The incidence of PONV in the placebo group in our present study was comparable with the incidence we found in a previous trial with remifentanil for MAC during ESWL. 7 As in this study, the onset of the symptoms was early (<60 min) and the duration was relatively short in most patients. The severity of the symptoms decreased over time. The majority of studies reported incidences of PONV in the range of 14±42%. 1 2 8 The lower doses of remifentanil and the combination with propofol or midazolam can probably explain the lower incidences of PONV in these studies in comparison with our data.
The potential bene®t of the ultra-short-acting remifentanil with respect to an earlier discharge from the PACU in comparison to long-acting analgesics and sedatives is limited by its emetic side-effect when given as a sole agent. In our study, PONV symptoms were the main reason preventing earlier discharge. As a consequence, the dolasetron prohylaxis directly improved postoperative recovery and decreased the time to readiness for discharge. 
